Immunome (IMNM) News Today → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free IMNM Stock Alerts $14.94 +0.23 (+1.56%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 10:55 AM | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Up to $14.71Immunome (NASDAQ:IMNM) Shares Gap Up to $14.71May 31 at 8:26 AM | marketbeat.comImmunome (NASDAQ:IMNM) Research Coverage Started at Piper SandlerPiper Sandler assumed coverage on Immunome in a research report on Friday. They set an "overweight" rating and a $27.00 price objective for the company.May 24, 2024 | msn.comImmunome (NASDAQ:IMNM): An Opportunity for Investors with Strong StomachsMay 23, 2024 | insidertrades.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Buys 2,000 Shares of StockMay 22, 2024 | marketbeat.comInsider Buying: Immunome, Inc. (NASDAQ:IMNM) Director Purchases 2,000 Shares of StockImmunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Jean Jacques Bienaime acquired 2,000 shares of the business's stock in a transaction dated Tuesday, May 21st. The shares were bought at an average cost of $13.57 per share, for a total transaction of $27,140.00. Following the transaction, the director now directly owns 9,615 shares in the company, valued at $130,475.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.May 22, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Up to $13.65Immunome (NASDAQ:IMNM) Shares Gap Up to $13.65May 21, 2024 | finance.yahoo.comInsider Buying: Immunome Inc's CEO Acquires 100,000 SharesMay 20, 2024 | businesswire.comImmunome Announces Completion of Purchase of Assets from AtrecaMay 17, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Stock Price Down 4%Immunome (NASDAQ:IMNM) Shares Down 4%May 17, 2024 | msn.comImmunome appoints CFOMay 17, 2024 | marketbeat.comImmunome, Inc. to Post FY2024 Earnings of ($0.76) Per Share, Leerink Partnrs Forecasts (NASDAQ:IMNM)Immunome, Inc. (NASDAQ:IMNM - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2024 earnings per share estimates for shares of Immunome in a research note issued on Tuesday, May 14th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($0.76)May 17, 2024 | businesswire.comImmunome Announces Promotion of Max Rosett to Chief Financial OfficerMay 16, 2024 | markets.businessinsider.comImmunome’s Promising Pipeline and Strategic Positioning Affirm Buy RatingMay 16, 2024 | marketbeat.comQ2 2024 Earnings Forecast for Immunome, Inc. (NASDAQ:IMNM) Issued By WedbushImmunome, Inc. (NASDAQ:IMNM - Free Report) - Analysts at Wedbush lowered their Q2 2024 earnings estimates for shares of Immunome in a report released on Tuesday, May 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.57) for the quarter, downMay 15, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Up 5.6%Immunome (NASDAQ:IMNM) Shares Up 5.6%May 14, 2024 | marketbeat.comImmunome's (IMNM) "Outperform" Rating Reaffirmed at WedbushWedbush reissued an "outperform" rating and set a $33.00 price target on shares of Immunome in a research report on Tuesday.May 14, 2024 | investorplace.comIMNM Stock Earnings: Immunome Beats EPS, Misses Revenue for Q1 2024May 14, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Down to $15.61Immunome (NASDAQ:IMNM) Shares Gap Down to $15.61May 14, 2024 | markets.businessinsider.comImmunome, Inc. Q1 Loss Increases, Misses EstimatesMay 14, 2024 | businesswire.comImmunome Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | businesswire.comImmunome to Present at 2024 Bank of America Healthcare ConferenceMay 2, 2024 | businesswire.comImmunome Appoints Kinney Horn as Chief Business OfficerApril 30, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Up to $13.82Immunome (NASDAQ:IMNM) Shares Gap Up to $13.82April 25, 2024 | businesswire.comImmunome Appoints Sandra M. Swain to Board of DirectorsApril 24, 2024 | marketbeat.com61,346 Shares in Immunome, Inc. (NASDAQ:IMNM) Acquired by Cerity Partners LLCCerity Partners LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 61,346 shares of the company's stock, valueApril 22, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Up to $15.48Immunome (NASDAQ:IMNM) Shares Gap Up to $15.48April 19, 2024 | finance.yahoo.comImmunome, Inc. (IMNM)April 17, 2024 | msn.comImmunome (IMNM) Price Target Increased by 8.72% to 36.04April 16, 2024 | msn.comGuggenheim Initiates Coverage of Immunome (IMNM) with Buy RecommendationApril 15, 2024 | marketbeat.comEmfo LLC Buys Shares of 59,165 Immunome, Inc. (NASDAQ:IMNM)Emfo LLC bought a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 59,165 shares of the company's stock, valued at approximately $633,000. Emfo LLC owned approximately 0.14% ofApril 15, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Given Average Rating of "Buy" by BrokeragesShares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have received a consensus rating of "Buy" from the five ratings firms that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers thaApril 5, 2024 | businesswire.comImmunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual MeetingApril 4, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Down 4.5%Immunome (NASDAQ:IMNM) Trading Down 4.5%April 4, 2024 | marketbeat.comQ1 2024 EPS Estimates for Immunome, Inc. (NASDAQ:IMNM) Reduced by WedbushImmunome, Inc. (NASDAQ:IMNM - Free Report) - Stock analysts at Wedbush dropped their Q1 2024 earnings estimates for shares of Immunome in a research note issued on Monday, April 1st. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.52) per share for the quarter, downApril 3, 2024 | marketbeat.comWedbush Weighs in on Immunome, Inc.'s Q1 2025 Earnings (NASDAQ:IMNM)Immunome, Inc. (NASDAQ:IMNM - Free Report) - Investment analysts at Wedbush issued their Q1 2025 earnings estimates for shares of Immunome in a research report issued on Monday, April 1st. Wedbush analyst D. Nierengarten anticipates that the company will post earnings of ($0.78) per share for theApril 1, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Given New $33.00 Price Target at WedbushWedbush lifted their target price on shares of Immunome from $27.00 to $33.00 and gave the stock an "outperform" rating in a research note on Monday.March 29, 2024 | marketbeat.comLeerink Partnrs Weighs in on Immunome, Inc.'s Q1 2024 Earnings (NASDAQ:IMNM)Immunome, Inc. (NASDAQ:IMNM - Free Report) - Leerink Partnrs lifted their Q1 2024 EPS estimates for Immunome in a research note issued to investors on Tuesday, March 26th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($1.71) for the quarter, upMarch 29, 2024 | investorplace.comIMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)March 28, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 3.7% Immunome (NASDAQ:IMNM) Stock Price Down 3.7%March 28, 2024 | businesswire.comImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsMarch 28, 2024 | businesswire.comImmunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired AssetsMarch 27, 2024 | finance.yahoo.comImmunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From AyalaMarch 26, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Up 5.3%Immunome (NASDAQ:IMNM) Trading Up 5.3%March 22, 2024 | finance.yahoo.comImmunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutionsMarch 20, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Down 5%Immunome (NASDAQ:IMNM) Shares Down 5%March 19, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Trading 7.3% Higher Immunome (NASDAQ:IMNM) Shares Up 7.3%March 18, 2024 | msn.comArrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapiesMarch 18, 2024 | businesswire.comArrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer TherapiesMarch 11, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 6.3% Immunome (NASDAQ:IMNM) Trading Down 6.3% Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Gold Set to EXPLODE! (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025. Click here now to download the free Precious Metals Buying Guide! IMNM Media Mentions By Week IMNM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNM News Sentiment▼1.790.82▲Average Medical News Sentiment IMNM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNM Articles This Week▼62▲IMNM Articles Average Week Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TNGX News Today ZNTL News Today ARCT News Today PRTC News Today AUPH News Today LBPH News Today NRIX News Today SPRY News Today CNTA News Today IRON News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNM) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWho are Nvidia’s New Silent Partners?Weiss RatingsMissed NVDA? Buy this AI stock NOWChaikin Analytics41 banks launch ‘crypto dollar’Stansberry ResearchGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist My Default Watchlist Adding Immunome, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.